Technical Analysis for SLXN - Silexion Therapeutics Ltd.
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
| F | 0.24 | -17.97% | -0.05 |
SLXN closed down 17.97 percent on Friday, November 1, 2024, on 50 percent of normal volume. The bears made the stock sink to a new 52-week low. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.
Earnings due: Nov 12
*** please verify all earnings dates ***| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Down | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| New 52 Week Closing Low | Bearish | 0.00% | |
| 180 Bearish Setup | Bearish Swing Setup | 0.00% | |
| New 52 Week Low | Weakness | 0.00% | |
| Wide Bands | Range Expansion | 0.00% | |
| Lower Bollinger Band Touch | Weakness | 0.00% | |
| Oversold Stochastic | Weakness | 0.00% | |
| Narrow Range Bar | Range Contraction | -17.97% | |
| Wide Bands | Range Expansion | -17.97% | |
| Oversold Stochastic | Weakness | -17.97% | |
| Narrow Range Bar | Range Contraction | -17.69% |
| Alert | Time |
|---|---|
| Fell Below Lower Bollinger Band | about 21 hours ago |
| Down 5% | 1 day ago |
| Down 3% | 1 day ago |
| Fell Below Previous Day's Low | 1 day ago |
| Down 2 % | 1 day ago |
Get a Trading Assistant
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 11/12/2024
Silexion Therapeutics is a pioneering clinical stage, oncology-focused biotechnology company dedicated to the development of innovative treatments for unsatisfactorily treated solid tumor cancers which have the mutated KRAS oncogene, generally considered to be the most common oncogenic gene driver in human cancers. The company conducted a Phase 2a clinical trial in its first-generation product which showed a positive trend in comparison to the control of chemotherapy alone. Silexion is committed to pushing the boundaries of therapeutic advancements in the field of oncology, and further developing its lead product candidate for locally advanced pancreatic cancer.
Sector: Financial Services
Industry: Shell Companies
Keywords: Biotechnology Cancer Oncology Chemotherapy Pancreatic Cancer Oncogenes Solid Tumor Cancers Human Cancers Ras Gtpase Oncogene Locally Advanced Pancreatic Cancer
Classification
Sector: Financial Services
Industry: Shell Companies
Keywords: Biotechnology Cancer Oncology Chemotherapy Pancreatic Cancer Oncogenes Solid Tumor Cancers Human Cancers Ras Gtpase Oncogene Locally Advanced Pancreatic Cancer
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 13.5576 |
| 52 Week Low | 0.2322 |
| Average Volume | 3,356,238 |
| 200-Day Moving Average | 8.27 |
| 50-Day Moving Average | 0.71 |
| 20-Day Moving Average | 0.32 |
| 10-Day Moving Average | 0.31 |
| Average True Range | 0.10 |
| RSI (14) | 25.93 |
| ADX | 42.4 |
| +DI | 15.99 |
| -DI | 35.88 |
| Chandelier Exit (Long, 3 ATRs) | 0.25 |
| Chandelier Exit (Short, 3 ATRs) | 0.53 |
| Upper Bollinger Bands | 0.42 |
| Lower Bollinger Band | 0.23 |
| Percent B (%b) | 0.05 |
| BandWidth | 56.64 |
| MACD Line | -0.26 |
| MACD Signal Line | -0.35 |
| MACD Histogram | 0.0868 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 0.34 | ||||
| Resistance 3 (R3) | 0.34 | 0.32 | 0.32 | ||
| Resistance 2 (R2) | 0.32 | 0.30 | 0.32 | 0.32 | |
| Resistance 1 (R1) | 0.28 | 0.28 | 0.27 | 0.27 | 0.31 |
| Pivot Point | 0.26 | 0.26 | 0.25 | 0.25 | 0.26 |
| Support 1 (S1) | 0.22 | 0.23 | 0.21 | 0.21 | 0.17 |
| Support 2 (S2) | 0.19 | 0.22 | 0.19 | 0.17 | |
| Support 3 (S3) | 0.16 | 0.19 | 0.16 | ||
| Support 4 (S4) | 0.15 |
